Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas

Journal of Medical Genetics

Volumn 40, Issue 2, 2003, Pages 109-114

  Kluwe, L ^a   Mautner, V ^b   Heinrich, B ^c   Dezube, R ^c   Jacoby, L B ^c   Friedrich, R E ^a   MacCollin, M ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Klinik Ochsenzoll   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; EXON; FOUNDER EFFECT; GENE DELETION; GENE MUTATION; GENETIC SCREENING; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; MOSAICISM; MULTIPLE CANCER; MUTATIONAL ANALYSIS; NERVOUS SYSTEM; NEURILEMOMA; NEUROFIBROMATOSIS; PARENT; PRIORITY JOURNAL;

EID: 0037323824     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.40.2.109     Document Type: Article

References (28)

1. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
2. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2) clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-61.
3. Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, Samii M, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenior G, Bijlsma E, Fahsold R, Dumanski J, de Jong P, Parry D, Eltridge R, Aurias A, Delattre O, Thomas G. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-5.
4. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fahsold R, Dumanski J, de Jong P, Parry D, Eltridge R, Aurias A, Delattre O, Thomas G. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-21.
5. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckle AJ, Gusella JF. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
6. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramesden R, Harris R. A genetic study of type 2 neurofibromatosis in the northwest of England and the UK. I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-6.
7. MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP, Pulaski K, Trofatter JA, Short MP, Bove C, Eldridge R, Parry DM, Gusella JF. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 1994;55:314-20.
8. Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Fünsterer C, Mautner VF. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet 1996;98:534-8.
9. Parry DM, MacCollin M, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59:529-39.
10. Ruttledge MH, Andermann A, Phelan CM, Claudio JO, Han F, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi V, Weksberg R, Kitamura K, Brandburn JM, Hall BD, Propping P, Rouleau GA. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-42.
11. Evans DGR, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35:450-5.
12. MacCollin M, Jacoby LB, Jones D, Ojemann R, Feit H, Gusella J. Somatic mosaicism of the neurofibromatosis 2 tumor suppressor gene. Neurology 1997;48:A429.
13. Evans DGR, Wallace A, Wu C, Trueman L, Ramsden R, Strachan T. Somatic mosaicism: A common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 1998;63:727-36.
14. Kluwe L, Mautner VF. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet 1998;7:2051-5.
15. Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology 2001;56:1433-43.
16. Gutmann D, Aylsworth A, Carey J, Korf B, Marks J, Pyeritz R, Rubenstein A, Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-7.
17. Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner VF. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 1998;77:228-33.
18. Jacoby LB, MacCollin M, Barone R, Ramesh V, Gusella JF. Frequency and distribution of NF2 mutations in schwannomas. Genes Chrom Cancer 1996;17:45-55.
19. MacCollin M, Braverman N, Viskochil D, Ruttledge M, Davis K, Ojemann R, Gusella J, Parry DM. A point mutation associated with a severe phenotype of neurofibromatosis 2. Ann Neurol 1996;40:440-5.
20. Kluwe L, Mautner VF, Parry DM, Jacoby LB, Baser M, Gusella J, Davis K, Stavrou D, MacCollin M. Parental origin of de novo mutations in sporadic neurofibromatosis 2 patients. Neurogenetics 2000;3:17-24.
21. Jacoby LB, MacCollin M, Parry DM, Kluwe L, Lynch J, Jones D, Gusella J. Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis. Neurogenetics 1999;2:101-8.
22. Jacoby LB, Jones D, Davis K, Kronn D, Short MP, Gusella J, MacCollin M. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 1997;61:1293-302.
23. Bourn D, Carter SA, Evans DGR, Goodship J, Coakham H, Strachan T. A mutation in the neurofibromatosis type 2 tumor-suppressor gene giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet 1994;55:69-73.
24. Bijsma EK, Wallace AF, Evans DG. Misleading linkage results in an NF2 presymptomatic test owing to mosaicism. J Med Genet 1997;34:934-6.
25. Zucman-Rossi J, Legoix P, Der Sarkissian H, Cherit G, Sor F, Bernardi A, Cazes L, Giraud S, Ollagnon E, Lenoir G, Thomas G. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet 1998;7:2095-101.
26. Kluwe L, Friedrich RE, Tatagiba M, Mautner VF. Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: a method based on tumor analysis. Genet Med 2002;4:27-30.
27. Jacoby LB, MacCollin MM, Louis DN, Mohney T, Rubio MP, Pulaski K, Trofatter JA, Kley N, Seizinger BR, Ramesh V, Gusella JF. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 1994;3:413-19.
28. Murgia A, Martella M, Vinanzi C, Polli R, Perilongo G, Opocher G. Somatic mosaicism in von Hippel-Lindau disease. Hum Mutat 2000;15:114.